Introduction

Glaucoma is a group of eye disorders characterised by damage to the optic nerve, often associated with elevated intraocular pressure (IOP). Left untreated, glaucoma can lead to irreversible vision loss. While several medical treatments are available to manage IOP and slow disease progression, the use of cannabis has gained attention as a potential alternative therapy. However, the enthusiasm surrounding cannabis in this context is tempered by several risks and limitations, which this article aims to explore.

Understanding cannabis and intraocular pressure

Cannabis, derived from the plant Cannabis sativa, contains active compounds called cannabinoids, including tetrahydrocannabinol (THC) and cannabidiol (CBD). THC, the psychoactive component, has been shown to lower IOP, a critical factor in glaucoma management. Research conducted as early as the 1970s suggested that smoking cannabis could reduce IOP for a few hours, leading to interest in its use as a treatment. However, these effects are transient and accompanied by numerous potential complications.

Temporary effects on intraocular pressure

The short-lived reduction in IOP is one of the significant drawbacks of using cannabis for glaucoma. Studies indicate that the IOP-lowering effect of cannabis lasts approximately three to four hours. Since glaucoma requires consistent IOP control to prevent optic nerve damage, a person would need to use cannabis multiple times a day, which is impractical and raises concerns about long-term health consequences. In contrast, standard glaucoma treatments like prostaglandin analogues or beta-blockers offer sustained effects with once- or twice-daily dosing.

Cardiovascular concerns

Cannabis use is associated with systemic side effects that can exacerbate underlying health conditions, including those commonly found in glaucoma patients, such as hypertension and cardiovascular disease. THC can cause tachycardia, hypotension, and other cardiovascular irregularities. Hypotension, in particular, poses a risk for glaucoma patients because it may reduce blood flow to the optic nerve, potentially worsening the disease despite reductions in IOP.

Neuropsychiatric effects

Frequent cannabis use can lead to cognitive impairment, dependency, and psychological issues, such as anxiety, depression, or psychosis, especially in predisposed individuals. The psychoactive effects of THC, including altered perception and motor function, are undesirable for glaucoma patients, particularly older adults who may already experience age-related cognitive decline or impaired mobility.

Respiratory risks

Smoking cannabis, a common mode of consumption, is associated with respiratory problems, including chronic bronchitis and reduced lung function. These issues are particularly concerning for older adults and those with preexisting respiratory conditions. Although alternative delivery methods, such as edibles or vaporisersvaporizers, avoid these respiratory risks, they do not eliminate the systemic side effects associated with THC.

Interaction with other medications

Many glaucoma patients are elderly and often take multiple medications for coexisting conditions. Cannabis has the potential to interact with these drugs, potentially altering their efficacy or increasing the risk of adverse effects. For instance, cannabis can interfere with the metabolism of drugs processed by the cytochrome P450 enzyme system, leading to higher or lower levels of these medications in the bloodstream. This interaction could result in suboptimal control of conditions like hypertension, diabetes, or cardiac arrhythmias.

Limited role of cannabidiol (CBD)

CBD, a non-psychoactive cannabinoid, has gained popularity for its purported therapeutic benefits, including anti-inflammatory and neuroprotective properties. However, studies on CBD’s effects on IOP have shown disappointing results. Research suggests that CBD alone may not lower IOP and, in some cases, might even raise it. This finding limits the applicability of CBD as a standalone treatment for glaucoma and underscores the need for more research on the therapeutic potential of cannabinoids.

Potential for addiction and abuse

Cannabis has a well-documented potential for addiction, with approximately 9% of users developing cannabis use disorder. Frequent use, as required for IOP control, increases the likelihood of dependency. This is particularly problematic for patients who may rely on cannabis not just for glaucoma but for other medical or recreational purposes, complicating their overall treatment plan.

Regulatory and legal challenges

The legal status of cannabis varies widely, complicating its use as a treatment for glaucoma. In some jurisdictions, cannabis remains illegal, limiting access for patients. Even in regions where it is legal, cannabis products lack standardisationstandardization and quality control. Variability in THC and CBD concentrations among products can lead to inconsistent effects, making it difficult for patients and clinicians to achieve reliable therapeutic outcomes.

Lack of long-term studies

One of the most significant gaps in understanding the role of cannabis in glaucoma management is the absence of robust long-term studies. Most research on cannabis and IOP has been short-term, focusing on acute effects rather than chronic use. Long-term studies are essential to determine whether the benefits of cannabis use outweigh the risks, especially given the progressive nature of glaucoma.

Alternatives to cannabis for glaucoma

Standard glaucoma treatments, such as eye drops (e.g., prostaglandin analogues, beta-blockers, and carbonic anhydrase inhibitors), laser therapy, and surgical interventions, offer more consistent and effective IOP control than cannabis. These treatments are backed by extensive clinical evidence and are recommended by major ophthalmological organisationsorganizations.

Additionally, research is ongoing to develop cannabinoid-based medications that target the endocannabinoid system without the psychoactive effects of THC. These therapies could potentially offer the benefits of cannabinoids while minimising systemic side effects.

Summary

While cannabis has demonstrated the ability to lower IOP, its short duration of action, systemic side effects, and potential for abuse make it a suboptimal choice for glaucoma management. The risks associated with cannabis, including cardiovascular and neuropsychiatric effects, interactions with other medications, and the lack of long-term safety data, underscore the need for caution in considering it as a treatment option.

For glaucoma patients, the priority should remain on evidence-based treatments that offer consistent and effective IOP control. As research continues, cannabinoid-based therapies may emerge as a viable alternative, but for now, cannabis is not recommended as a primary treatment for glaucoma. Patients interested in exploring cannabis should consult with their healthcare provider to weigh the potential risks and benefits and to ensure a comprehensive approach to their glaucoma care.